Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy
Authors:
Open Access
- 24 December 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 48 (5) , 569-572
Abstract
Objectives. Dermatologists and rheumatologists have differed in their use of serial liver biopsy and liver function tests (LFT) to monitor the risk of hepatic fibrosis in long-term MTX therapy. It is judged safe to monitor LFT only in RA. Whilst there are few studies in PsA to justify this approach, it is widely used in rheumatology practice. The study aimed to assess prevalence of hepatic fibrosis in both psoriasis and PsA patients on long-term MTX therapy. Methods. A prospective study of 54 patients with psoriatic disease had a liver biopsy according to dermatology guidelines on long-term MTX treatment with full assessment of risk factors. Previously, monitoring these patients was in accordance with ACR guidelines with 3-monthly LFT. Results. MTX treatment duration was a mean of 6.9 years, with a mean cumulative dose of 4396 mg. There were no cases of advanced fibrosis or of cirrhosis and mild early fibrosis in 11 (22%) patients. The presence of early mild changes was related to the number of risk factors that the patient had for hepatic fibrosis [also the risk factors for non-alcoholic steatohepatitis (NASH)]. Pro-collagen 3 N-terminal peptide (PIIINP) was unhelpful in PsA and frequently elevated despite normal liver biopsy. Conclusions. Despite other risk factors for NASH, monitoring for hepatic fibrosis using serial liver function and ACR guidelines tests alone as in RA appears safe in psoriasis and PsA. Liver biopsy ought to be considered to assess the liver if LFT are persistently elevated. PIIINP is misleading in active PsA.Keywords
This publication has 18 references indexed in Scilit:
- Psoriatic arthritis, methotrexate and the liver--are rheumatologists putting their patients at risk?Rheumatology, 2008
- Evaluation of Liver Fibrosis: A Concise ReviewAmerican Journal of Gastroenterology, 2004
- Clinical and Histologic Spectrum of Nonalcoholic Fatty Liver Disease Associated With Normal Alt ValuesHepatology, 2003
- Role of non‐alcoholic steatohepatitis in methotrexate‐induced liver injuryJournal of Gastroenterology and Hepatology, 2001
- Liver Biopsy in Psoriatic Arthritis to Detect Methotrexate HepatotoxicityJCR: Journal of Clinical Rheumatology, 2001
- Methotrexate in psoriasis: Consensus conferenceJournal of the American Academy of Dermatology, 1998
- METHOTREXATE HEPATOTOXICITYRheumatic Disease Clinics of North America, 1997
- Methotrexate-lnduced Liver CirrhosisDermatology, 1996
- Methotrexate for Rheumatoid ArthritisArthritis & Rheumatism, 1994
- Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis. A word of caution in light of the expanding use of this 'steroid-sparing' agentArchives of internal medicine (1960), 1990